LGALS3 expression based on
PAAD : Pancreatic adenocarcinoma *
Please note that low number(<10) of normal samples considered.
Comparison Statistical significance Normal-vs-Primary 5.670400E-02
Pan-cancer view
Methylation
Survival
Correlated genes
DepMap
PAAD : Pancreatic adenocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Cancer stage information is not available for 3 samples.
Show statistics
Hide statistics
Comparison Statistical significance
Normal-vs-Stage1
3.742200E-01
Normal-vs-Stage2
2.858100E-02
Normal-vs-Stage3
3.514400E-01
Normal-vs-Stage4
5.981900E-02
Stage1-vs-Stage2
1.015370E-01
Stage1-vs-Stage3
7.882800E-01
Stage1-vs-Stage4
2.104200E-01
Stage2-vs-Stage3
3.373800E-01
Stage2-vs-Stage4
7.440600E-01
Stage3-vs-Stage4
4.260200E-01
Pan-cancer view
Methylation
Survival
Correlated genes
DepMap
PAAD : Pancreatic adenocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Patient race information is not available for 5 samples.
Show statistics
Hide statistics
Comparison Statistical significance
Normal-vs-Caucasian
6.606100E-02
Normal-vs-AfricanAmerican
1.152760E-01
Normal-vs-Asian
3.215600E-02
Caucasian-vs-AfricanAmerican
6.831200E-01
Caucasian-vs-Asian
1.402410E-01
AfricanAmerican-vs-Asian
2.154400E-01
Pan-cancer view
Methylation
Survival
Correlated genes
DepMap
PAAD : Pancreatic adenocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Patient gender information is not available for 1 sample.
Show statistics
Hide statistics
Comparison Statistical significance
Normal-vs-Male
4.436300E-02
Normal-vs-Female
8.486500E-02
Male-vs-Female
1.375040E-01
Pan-cancer view
Methylation
Survival
Correlated genes
DepMap
PAAD : Pancreatic adenocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Patient age information is not available for 1 sample.
Show statistics
Hide statistics
Comparison Statistical significance
Normal-vs-Age(21-40Yrs)
5.423800E-01
Normal-vs-Age(41-60Yrs)
5.083900E-02
Normal-vs-Age(61-80Yrs)
7.971900E-02
Normal-vs-Age(81-100Yrs)
7.974500E-04
Age(21-40Yrs)-vs-Age(41-60Yrs)
4.637400E-01
Age(21-40Yrs)-vs-Age(61-80Yrs)
6.161000E-01
Age(21-40Yrs)-vs-Age(81-100Yrs)
5.717800E-01
Age(41-60Yrs)-vs-Age(61-80Yrs)
3.301000E-01
Age(41-60Yrs)-vs-Age(81-100Yrs)
2.237000E-01
Age(61-80Yrs)-vs-Age(81-100Yrs)
3.029800E-02
Pan-cancer view
Methylation
Survival
Correlated genes
DepMap
PAAD : Pancreatic adenocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Drinking status is not available for 80 samples.
Show statistics
Hide statistics
Comparison Statistical significance
Normal-vs-Non Drinker
3.993800E-02
Normal-vs-Daily Drinker
5.503900E-02
Normal-vs-Weekly Drinker
2.152200E-01
Normal-vs-Occasional Drinker
8.541800E-02
Normal-vs-Social Drinker
1.291980E-01
Non Drinker-vs-Daily Drinker
7.170400E-01
Non Drinker-vs-Weekly Drinker
1.770030E-01
Non Drinker-vs-Occasional Drinker
6.655400E-01
Non Drinker-vs-Social Drinker
1.019190E-01
Daily Drinker-vs-Weekly Drinker
1.471770E-01
Daily Drinker-vs-Occasional Drinker
9.240800E-01
Daily Drinker-vs-Social Drinker
8.445900E-02
Weekly Drinker-vs-Occasional Drinker
1.716030E-01
Weekly Drinker-vs-Social Drinker
8.989600E-01
Occasional Drinker-vs-Social Drinker
1.059610E-01
Pan-cancer view
Methylation
Survival
Correlated genes
DepMap
PAAD : Pancreatic adenocarcinoma
Subtype descriptions Grade 1 Well differentiated (low grade)
Grade 2 Moderately differentiated (intermediate grade) Grade 3 Poorly differentiated (high grade)
Grade 4 Undifferentiated (high grade)
Show statistics
Hide statistics
Comparison Statistical significance
Normal-vs-Grade 1
2.636600E-01
Normal-vs-Grade 2
1.409940E-02
Normal-vs-Grade 3
1.394350E-02
Normal-vs-Grade 4
1.000000E+00
Grade 1-vs-Grade 2
5.62659999999715E-05
Grade 1-vs-Grade 3
8.48450000000556E-05
Grade 1-vs-Grade 4
2.636600E-01
Grade 2-vs-Grade 3
4.843200E-01
Grade 2-vs-Grade 4
1.409940E-02
Grade 3-vs-Grade 4
1.394350E-02
Pan-cancer view
Methylation
Survival
Correlated genes
DepMap
PAAD : Pancreatic adenocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Diabetes status information is not available for 30 samples.
Show statistics
Hide statistics
Comparison Statistical significance
Normal-vs-Diabetic
6.970100E-02
Normal-vs-NonDiabetic
5.612300E-02
Diabetic-vs-NonDiabetic
9.794000E-01
Pan-cancer view
Methylation
Survival
Correlated genes
DepMap
PAAD : Pancreatic adenocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Pancreatitis status is not available for 39 samples.
Show statistics
Hide statistics
Comparison Statistical significance
Normal-vs-Pancreatitis
2.444400E-02
Normal-vs-NoPancreatitis
6.635600E-02
Pancreatitis-vs-NoPancreatitis
8.390600E-01
Pan-cancer view
Methylation
Survival
Correlated genes
DepMap
PAAD : Pancreatic adenocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Nodal metastais status is not available for 1 sample and cancer in nearby lymph nodes cannot be measured (NX) in 4 samples.
pathologic_N descriptions N0 No regional lymph node metastasis
N1 Metastases in 1 to 3 axillary lymph nodes N2 Metastases in 4 to 9 axillary lymph nodes
N3 Metastases in 10 or more axillary lymph nodes
Show statistics
Hide statistics
Comparison Statistical significance
Normal-vs-N0
1.071410E-01
Normal-vs-N1
3.286300E-02
N0-vs-N1
5.020600E-01
Pan-cancer view
Methylation
Survival
Correlated genes
DepMap
PAAD : Pancreatic adenocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Whole exome sequencing data is not available for 3 samples.
TP53 mutation status is obtained from TCGA whole exome sequencing data. We downloaded Mutation Annotation Format (MAF) files (derived from VarScan2) from Genomic Data Commons portal. The sample with/without TP53 mutation were matched with RNA-seq data
Show statistics
Hide statistics
Comparison Statistical significance
Normal-vs-TP53-Mutant
5.576800E-03
Normal-vs-TP53-NonMutant
3.395200E-01
TP53-Mutant-vs-TP53-NonMutant
1.51729999675609E-08
Pan-cancer view
Methylation
Survival
Correlated genes
DepMap
